Carcinoid Cancer - Pipeline Review, Q2 2011

Description: Carcinoid Cancer - Pipeline Review, Q2 2011

Summary

Global Markets Direct's, 'Carcinoid Cancer - Pipeline Review, Q2 2011', provides an overview of the Carcinoid Cancer therapeutic pipeline. This report provides information on the therapeutic development for Carcinoid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Carcinoid Cancer. 'Carcinoid Cancer - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Carcinoid Cancer.
- A review of the Carcinoid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Carcinoid Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Carcinoid Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Carcinoid Cancer pipeline depth and focus of Carcinoid Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Carcinoid Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Carcinoid Cancer
Carcinoid Cancer Therapeutics under Development by Companies
Carcinoid Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Carcinoid Cancer Therapeutics - Products under Development by Companies
Carcinoid Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Carcinoid Cancer Therapeutics Development
Genzyme Corporation
F. Hoffmann-La Roche Ltd.
Ipsen S.A.
Novartis AG
EntreMed, Inc.
Evotec Aktiengesellschaft
Molecular Insight Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.
Camurus AB
Cylene Pharmaceuticals, Inc.
Carcinoid Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Pasireotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EPO906 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atiprimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LX1032 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DG3173 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onalta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Panzem NCD + Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 + Vatalanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R&D Progress
Sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PEG-interferon alfa-2b + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temsirolimus + Vinorelbin Ditartrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Panitumumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Interferon alfa + Fluourouracil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dacarbazine+bortezomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + S-fluorouracil + Leucovorin + Oxaliplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Panzem + Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pasireotide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pasireotide LAR + Everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CAM2029 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pazopanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sandostatin LAR + RAD001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carcinoid Cancer Therapeutics – Drug Profile Updates
Carcinoid Cancer Therapeutics - Discontinued Products
Carcinoid Cancer - Featured News
Oct 11, 2010: Phase III Novartis Data Show Potential Benefit Of Afinitor Plus Sandostatin LAR In Patients With Advanced Neuroendocrine Tumors
Apr 12, 2010: Affinium Begins Phase I Clinical Trial Using Optimized Oral Formulation Of AFN-1252
Apr 12, 2010: Molecular Insight's Onalta Phase II Data Published In Journal Of Clinical Oncology
Jul 21, 2009: LX1032 Receives Orphan Drug Designation From EMEA For Carcinoid Syndrome
Jul 08, 2009: LX1032 Phase 2 Clinical Trial Initiated By Lexicon In Patients With Carcinoid Syndrome
May 27, 2009: Lexicon To Present Clinical Data For LX1032 At Digestive Disease Week
May 14, 2009: Molecular Insight Pharmaceuticals, Inc. Receives European Medicines Agency Approval To Proceed With Phase 3 Development of Onalta
Oct 23, 2008: Exelixis Reports Positive Phase 1 Data For XL281 At EORTC-NCI-AACR Symposium
Jun 18, 2008: Molecular Insight Pharmaceuticals, Inc. Reports Onalta Tissue Distribution Data Support Clinical Development Program
May 16, 2008: Callisto Pharmaceuticals Reports Promising Interim Phase II Data For Atiprimod In Advanced Carcinoid Cancer

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Carcinoid Cancer, Q2 2011
Products under Development for Carcinoid Cancer – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Genzyme Corporation, 2011
F. Hoffmann-La Roche Ltd., 2011
Ipsen S.A., 2011
Novartis AG, 2011
Entremed, Inc., 2011
Evotec Aktiengesellschaft, 2011
Molecular Insight Pharmaceuticals, Inc., 2011
Lexicon Pharmaceuticals, Inc., 2011
Camurus AB, 2011
Cylene Pharmaceuticals, Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Carcinoid Cancer Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Carcinoid Cancer, Q2 2011
Products under Development for Carcinoid Cancer – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011
Ordering:

Order Online - http://www.researchandmarkets.com/reports/1801462/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Carcinoid Cancer - Pipeline Review, Q2 2011
Web Address: http://www.researchandmarkets.com/reports/1801462/
Office Code: SCD23GZY

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>Single User:</td>
<td>USD 500</td>
</tr>
<tr>
<td></td>
<td>Site License:</td>
<td>USD 1000</td>
</tr>
<tr>
<td></td>
<td>Enterprisewide:</td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof  [ ]
First Name: ___________________________________________  Last Name: _______________________________
Email Address: * _______________________________________
Job Title: __________________________________________
Organisation: _________________________________________
Address: ___________________________________________
City: _______________________________________________
Postal / Zip Code: ___________________________________
Country: ___________________________________________
Phone Number: _______________________________________
Fax Number: _______________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp